OLMA logo

OLEMA PHARMACEUTICALS INC

OLMANASDAQ
🏆 #2686 by market capEarnings Nov 10US Equity
$7.48▲ $0.43 (+6.17%)
Pre-market · at close
🔔
Track OLMA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.2%
7d▲ 6.4%
14d▲ 9.0%
30d▼ 12.5%
ytd▼ 70.1%
1y▼ 13.4%
🏦Market Cap
$655M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$6.87 – $7.49
52-Week Range
$6.24 – $36.26
Volume (shares)
111,001
Avg Volume (shares)
—
Shares Outstanding
87.5M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-2.12
Dividend Yield
—
Dilution (1yr)
+55.5%
OLMA logo

OLEMA PHARMACEUTICALS INC

OLMA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$179M▲ +25.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$147M▲ +40.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
91.3M▲ +55.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$47M▼ −$91M YoY
StockOtter · stockotter.space

About OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
18 analysts
Strong Buy6
Buy10
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.